Vaccine therapy for advanced colorectal and small bowel cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a vaccine therapy for people with advanced colorectal or small bowel cancer that has spread or can't be removed. The vaccine targets a protein found on cancer cells to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced colorectal or small bowel cancer that has continued to grow after standard treatments.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have at least one tumor outside the brain that can be measured on scans.
- You have adequate blood cell counts and organ function (kidney, liver).
- You are not pregnant and agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize colorectal cancer. It is for people who had surgery for colorectal cancer that spread to the liver and are now at high risk for the cancer returning.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests a combination of four drugs (SX-682, TriAdeno vaccine, retifanlimab, and N-803) to see if they can help people with colorectal cancer that has spread. It may be an option if you have already tried at least two standard treatments or cannot take them.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.